BIRC5 and melanoma: Additionally, the GEO dataset GSE50509 [47], which contains transcriptomic data for melanoma patients who experienced disease progression after treatment with BRAFV600 inhibitors (prog) matched with pre-treatment melanoma samples (pre), was analyzed to assess changes in BIRC5 expression.